Figure 3.

tsRNA-1599 regulates endothelial angiogenic effects in vitro. (A) HUVECs were transfected with negative control (NC) mimic, tsRNA-1599 mimic, or left untreated (Ctrl) for 24 h. The levels of tsRNA-1599 expression were detected by qRT-PCRs (n = 3, *P < 0.05 vs. Ctrl group, One-way ANOVA followed by Bonferroni's post hoc test). (B and C) HUVECs were transfected with NC mimic (30 nM), tsRNA-1599 mimic (30 nM), NC inhibitor (30 nM, tsRNA-1599 inhibitor (30 nM), treated with aflibercept (40 μg/mL), or left untreated (Ctrl) for 24 h, and then treated with or without CoCl₂ (300 μmol/L) for 24 h. The viability of HUVECs was determined by CCK-8 assays (B, n = 5). Calcein-AM/PI assays were conducted to detect cell apoptosis (C, n = 5, Scale bar, 20 μm). *P < 0.05 vs. Ctrl group; ^#P < 0.05 between the marked group; One-way ANOVA followed by Bonferroni's post hoc test. (D - F) HUVECs were transfected with NC mimic, tsRNA-1599 mimic, NC inhibitor, tsRNA-1599 inhibitor, treated with aflibercept (40 μg/mL), or left untreated (Ctrl) for 24 h. The proliferation ability of HUVECs was determined by EdU assays (D, n = 5, Scale bar, 20 μm). Cell migration and quantitative analysis was conducted by transwell assays (E, n = 5, Scale bar, 20 μm). Tube formation assays and quantitative analysis were conducted to detect the tube formation ability of HUVECs (F, n = 5, Scale bar, 50 μm). *P < 0.05 vs. Ctrl group; ^#P < 0.05 between the marked group; One-way ANOVA followed by Bonferroni's post hoc test.